148 results about "Papilloma" patented technology

An isolated protein sequence or peptide from the E2, E6 or E7 early coding region of human papillomavirus (HPV) that is soluble in an aqueous medium, and characterized by a relative paucity of tryptophan, methionine and cysteine residues, and a relative abundance of glycine and asparagine residues. Also disclosed are isolated protein sequences or peptides from the E2, E6 or E7 early coding regions of HPV 16 and 18 and methodologies for detecting or diagnosing cancer or cellular abnormalities. Detection or diagnosis of Cancer or cellular abnormalities may include detecting or diagnosing pre-cancerous or pre-malignant conditions, cervical dysplasia, cervical carcinoma, koilocytosis, hyperkeratosis, intraepithelial lesions, and other cancers. A methodology for detecting or diagnosing cancer or cellular abnormalities comprises the steps of (1) reacting a sample of body fluid or tissue with isolated protein sequences or peptides; (2) forming an antibody-peptide complex; and (3) detecting the antibody-peptide complex.

The invention provides traditional Chinese medicine for treating breast diseases, which is formed by mixing Chinese angelica, red paeony root, peach kernels, red flower, salvia miltiorrhiza, zedoary turmeric oil, rhizoma corydalis, szechuan lovage rhizome, lumbricus, pangolin scales, uniflower swisscentaury root, fritillaria thunbergii, spina gleditsiae, cowherb seeds, angelica root, mongolian snakegourd root, concha ostreae, pericarpium citri reticulatae viride, nutgrass galingale rhizome, tangerine seeds, radix bupleuri, dandelion, rhizoma pleionis, fructus forsythiae, astragalus root, codonopsis pilosula, liquorice, frankincense, myrrh, poria cocos and oldenlandia diffusa. The traditional Chinese medicine has the effects of invigorating Qi and enriching the blood, invigorating the blood circulation and softening the hard lumps, activating the meridians and detoxicating, soothing the depressed livers and regulating the flow of Qi, softening and resolving the hard lumps, invigorating the spleens and reducing the phlegm, strengthening the healthy energy and eliminating the pathogenic factors and can be used for treating hyperplasia of mammary gland, acute or chronic mastitis, breast fibroadenoma, intraductal papilloma, breast lump, breast scrofula, breast carbuncle and breast cancer.

The invention discloses a primer, a probe and a kit for fluorescence PCR (Polymerase Chain Reaction) detection of 18 types of high-risk human papilloma viruses. Different typing kits are detected by adding different specificity probes; the DNAs (Deoxyribose Nucleic Acids)) of 18 types of common high-risk human papilloma viruses internationally recognized and closely related to the cervical cancer can be detected once; and typing detection is carried out on HPV (Human Papilloma Virus)16 and 18. The application provides 6 universal primers and 18 specific molecular beacon probes. The DNAs of the 18 types of common high-risk human papilloma viruses can be amplified by the 6 universal primers; and meanwhile, the 18 probes are the specific molecular beacon probes designed by aiming at the 18 high-risk types; different types of probes are added according to the detection need and combined as the kits aiming at the detection need of the different high-risk types; and at the same time, the added probes are marked by different report genes, so that the purpose of carrying out typing detection on the high-risk HPV is achieved.

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and / or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP).

Topical drug compositions of this invention contain delayed type contact sensitizing haptens in a unique non-flowable, non-toxic, non-volatile, anhydrous gel composition to achieve retained site application on warts and other human papilloma virus (HPV) skin infections. The preferred gelled compositions contain, but are not limited to, the sensitizing haptens, squaric acid dibutylester and diphenylcyclopropenone in optimized blends of Polysorbate 80, Isopropyl myristate uniquely gelled with Polyoxyl 40 stearate to form a penetrant of keratinized epitheliiuim of warts for direct application wherein virucidal pharlacologic action is induced by Th-1 cell mediated immune responses with resultant releases of CD4 helper T cells, CD8 killer T cells and cytokines to attack the human papilloma viruses. The commonly used vehicles with these contact sensitizers are acetone, petrolatum, or water containing emulsion creams which do not have the capacity to penetrate the keratinized wart surfaces and are therefore minimally effective in treating warts.

The invention discloses a tumor immunization method combining with chimeric antigen T cells targeting at PD-1 (programmed cell death protein 1) and EGFR (epidermal growth factor receptor) and also discloses a plasmid vector for implementing the method. In combination with fourth-generation CAR-T (chimeric antigen receptor T) cells targeting at PD-1 and EGFR, a lentiviral vector is used as a CAR-T vector basic structure, and truncated EGFR antibody is selected as a CAR core to give tumor targeted enrichment to play, tumor-killing effect is given to play in conformity with overexpressed immune checkpoint inhibitor PD-1 monoclonal antibody; by constructing the fourth-generation CAR-T vector for co-expressing various regulatory factors such as IL21, CCR4 and Bcl2, the killing, homing and persistent proliferating abilities of CAR-T cells are improved. EP-CAR T (esophageal papilloma chimeric antigen receptor T) cells are treated by transducing patient's autologous T-lymphocytes in vitro, amplifying suitably and transducing back to the patient's body via autologous transfusion, and no reports on similar designs of CAR-T cells are provided at present.

A detector for detecting and simultaneously diagnosing at least one subtype of human papilloma viruses (HPV) contained in a biological sample is provided. The detector comprises: a carrier, a plurality of micro-dots immobilized on the carrier, wherein each micro-dot is for identifying one particular HPV subtype, and the HPV subtype is one selected from a group consisting of 39 different HPV subtypes; and at least one oligonucleotide sequence contained in each the micro-dot that is specific to the one particular HPV subtype, wherein the at least one oligonucleotide sequence serves as a detection probe that hybridizes specifically with an L1 gene sequence of the one particular HPV subtype to form a hybridization complex as a detection indicator, so that each micro-dot identifies one particular HPV subtype via a corresponding oligonucleotide of the one particular HPV subtype, and thereby detecting and simultaneously identifying subtypes of human papilloma viruses.

Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

The invention relates to methods for producing papilloma-derived nanosphere particles that contain therapeutic, diagnostic, or other agents. The invention also provides nanosphere particle preparations that are useful for selectively delivering therapeutic, diagnostic, and / or other agents to cancer cells of subjects without eliciting a serotype-specific immunogenic response in the subjects.

The invention relates to primers and a method for detecting and typing human papilloma viruses (HPV) infecting esophageal cells (such as esophageal mucosa cells). In particular, the invention designs a set of brand-new primers (including amplification primers and extension primers) based on the mass spectrometry detection technology of a matrix assisted laser desorption / ionization time-of-flight mass spectrometry system (MALDI-TOF-MS), thus realizing detection and typing of 15 types infecting the esophageal cells.

The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudo-virus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudo-viruses (VLPs with plasmids inside). Oral administration of the pseudo-viruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudo-virus induces stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

[Problem] To provide a marker which serves as a measure for the treatment of breast cancer. [Solution] A kit for the diagnosis of breast cancer, which comprises an anti-LAT1 monoclonal antibody and / or a method for diagnosing breast cancer using an anti-LAT1 monoclonal antibody. Among mammary gland neoplastic lesions, ductal carcinoma in situ, which is malignant, undergoes the expression of LAT1 at a significantly high level compared with intraductal breast papilloma, which is benign. Therefore, an anti-LAT1 monoclonal antibody is useful for the discrimination between the two lesions. Further, LAT1 is expressed at a high level in most of triple-negative infiltrating carcinomas which are negative for all of ER, PgR and HER2 that are conventional molecular targeting markers for breast cancer and for which there is no proper molecular targeted therapy method. Therefore, LAT1 can be used as a novel molecular targeting marker for breast cancer. The expression of LAT1 can be diagnosed by the present immunohistological method, and the development of a molecular targeted therapy method in which LAT1 is targeted is effective.